Your browser is no longer supported. Please, upgrade your browser.
VTVT vTv Therapeutics Inc. daily Stock Chart
VTVT [NASD]
vTv Therapeutics Inc.
Index- P/E- EPS (ttm)-1.64 Insider Own0.90% Shs Outstand32.51M Perf Week-7.53%
Market Cap139.79M Forward P/E- EPS next Y-1.57 Insider Trans1.87% Shs Float6.83M Perf Month-21.82%
Income-15.90M PEG- EPS next Q-0.42 Inst Own41.30% Short Float4.47% Perf Quarter-27.85%
Sales0.10M P/S1456.18 EPS this Y48.40% Inst Trans-1.48% Short Ratio7.44 Perf Half Y-8.32%
Book/sh-14.06 P/B- EPS next Y9.70% ROA-39.10% Target Price17.00 Perf Year-13.83%
Cash/sh0.63 P/C6.82 EPS next 5Y- ROE13.90% 52W Range3.57 - 8.09 Perf YTD-10.97%
Dividend- P/FCF- EPS past 5Y- ROI68.90% 52W High-46.82% Beta-
Dividend %- Quick Ratio1.80 Sales past 5Y- Gross Margin- 52W Low20.49% ATR0.38
Employees51 Current Ratio1.80 Sales Q/Q-60.50% Oper. Margin- RSI (14)34.65 Volatility7.85% 8.95%
OptionableNo Debt/Eq- EPS Q/Q8.60% Profit Margin- Rel Volume1.55 Prev Close4.26
ShortableYes LT Debt/Eq- EarningsJan 31 AMC Payout- Avg Volume40.96K Price4.30
Recom1.30 SMA20-6.62% SMA50-25.52% SMA200-20.09% Volume63,439 Change0.94%
Sep-26-16Initiated H.C. Wainwright Buy $13
Sep-04-15Initiated Canaccord Genuity Buy $15
Aug-24-15Initiated Stifel Buy $17
Aug-24-15Initiated Piper Jaffray Overweight $24
Dec-04-17 07:55AM  Market Trends Toward New Normal in Patterson-UTI Energy, SAExploration, vTv Therapeutics, Outfront Media, Mylan N.V, and Axcelis Technologies Emerging Consolidated Expectations, Analyst Ratings GlobeNewswire
Nov-13-17 07:30AM  vTv to Host Key Opinion Leader Event to Discuss the Current State of Clinical Development in Alzheimers Disease Business Wire
Nov-08-17 04:35PM  vTv Therapeutics Initiates Phase 1b/2 Study Evaluating TTP399 for the Treatment of Type 1 Diabetes Business Wire
Nov-06-17 12:42PM  ETFs with exposure to vTv Therapeutics, Inc. : November 6, 2017 Capital Cube
Nov-03-17 10:05AM  vTv Therapeutics, Inc. :VTVT-US: Earnings Analysis: Q3, 2017 By the Numbers : November 3, 2017 Capital Cube
Nov-02-17 08:30AM  Report: Developing Opportunities within Echelon, NII Holdings, ANI Pharmaceuticals, Zion Oil & Gas, vTv Therapeutics, and Sears Holdings Future Expectations, Projections Moving into 2018 GlobeNewswire
05:50AM  VTv Therapeutics reports 3Q loss Associated Press
Nov-01-17 04:30PM  vTv Therapeutics Reports Third Quarter 2017 Financial and Operational Results Business Wire
Oct-30-17 07:00AM  vTv Therapeutics to Present on Azeliragon at the 10th Clinical Trials on Alzheimers Disease (CTAD) Business Wire
Oct-12-17 08:52AM  Why vTv Therapeutics (VTVT) Could Be Positioned for a Surge Zacks
Oct-11-17 12:11PM  ETFs with exposure to vTv Therapeutics, Inc. : October 11, 2017 Capital Cube +6.06%
Sep-07-17 07:00AM  vTv Therapeutics Presents Further Dose Response Analysis from Phase 2 Study of its GLP-1 Receptor Agonist at 53rd Annual Meeting of the European Association for the Study of Diabetes Business Wire
Sep-06-17 02:56PM  vTv Therapeutics snags funding for study of its diabetes-targeting drug American City Business Journals +6.78%
07:00AM  JDRF and vTv Therapeutics Announce Collaboration on Phase 2 Study of Novel Treatment for Type 1 Diabetes Business Wire
Aug-31-17 09:59PM  ETFs with exposure to vTv Therapeutics, Inc. : September 1, 2017 Capital Cube
Aug-24-17 10:30AM  vTv Therapeutics, Inc. :VTVT-US: Earnings Analysis: Q2, 2017 By the Numbers : August 24, 2017 Capital Cube
Aug-03-17 08:30AM  vTv Therapeutics Announces Issuance of U.S. Patent Covering Methods of Treatment Using Azeliragon Business Wire
05:06AM  VTv Therapeutics reports 2Q loss Associated Press
Aug-02-17 04:30PM  vTv Therapeutics Reports Second Quarter 2017 Financial and Operational Results Business Wire
Jul-20-17 03:08PM  'We're not going to be taken off' vTv Therapeutics CEO responds to NASDAQ's delisting warning American City Business Journals
Jul-13-17 04:30PM  vTv Therapeutics to Present Two Posters at the 2017 Alzheimer's Association International Conference Business Wire
Jun-11-17 04:00PM  vTv Therapeutics Presents Data Highlighting Further Potential of TTP273 at American Diabetes Association 77th Scientific Sessions Business Wire
Jun-08-17 04:30PM  vTv Therapeutics to Present Two Posters at the American Diabetes Associations 77th Scientific Sessions Business Wire
Jun-01-17 07:00AM  vTv Therapeutics Completes Enrollment of Part B of Pivotal Phase III STEADFAST Trial Evaluating Azeliragon for the Treatment of Patients with Mild Alzheimers Disease Business Wire
May-24-17 08:00AM  Corporate insiders have sold $4B in stock in 30 days; here's who's buying and selling in the Triad American City Business Journals
May-22-17 02:18PM  ETFs with exposure to vTv Therapeutics, Inc. : May 22, 2017 Capital Cube
May-05-17 11:11AM  vTv Therapeutics, Inc. :VTVT-US: Earnings Analysis: Q1, 2017 By the Numbers : May 5, 2017 Capital Cube
May-04-17 04:28PM  ETFs with exposure to vTv Therapeutics, Inc. : May 4, 2017 Capital Cube
May-03-17 06:25PM  VTv Therapeutics reports 1Q loss Associated Press
04:30PM  vTv Therapeutics Reports First Quarter 2017 Financial and Operational Results Business Wire
Apr-05-17 05:42PM  ETFs with exposure to vTv Therapeutics, Inc. : April 5, 2017 Capital Cube
Mar-29-17 08:01AM  VTV THERAPEUTICS INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits
Mar-15-17 10:05AM  vTv Therapeutics, Inc. :VTVT-US: Earnings Analysis: Q4, 2016 By the Numbers : March 15, 2017 Capital Cube
Mar-10-17 01:30PM  vTv Therapeutics to Present at Two Upcoming Annual Investor Conferences Business Wire
Mar-02-17 01:04PM  VTV THERAPEUTICS INC. Financials
Feb-28-17 04:56PM  VTV THERAPEUTICS INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exh
Feb-27-17 07:32PM  VTv Therapeutics reports 4Q loss Associated Press +7.91%
06:15PM  vTv Therapeutics Reports 2016 Fourth Quarter and Full Year Financial and Operational Results and Recent Highlights Business Wire
Feb-24-17 09:26AM  VTV THERAPEUTICS INC. Files SEC form 10-K, Annual Report
Jan-25-17 08:40AM  vTv Therapeutics (VTVT) in Focus: Stock Moves 6.7% Higher Zacks
Dec-15-16 05:02PM  VTV THERAPEUTICS INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits
Dec-14-16 04:30PM  vTv Therapeutics Announces Positive Topline Results from Phase 2 Study of TTP273 in Type 2 Diabetes Business Wire
Nov-16-16 09:03AM  New Pre-Clinical Data on a vTv Therapeutics Small Molecule Drug Candidate Against Parkinsons Disease to be Presented at the Society for Neuroscience 2016 Meeting in San Diego Business Wire
Nov-15-16 04:24PM  Horizon Technology Finance Leads $25 Million Venture Loan Facility for vTv Therapeutics GlobeNewswire +9.88%
07:27AM  Applied Materials (AMAT) Q4 Earnings: Surprise in Store?
Nov-14-16 09:24AM  Can JD.com (JD) Stock Surprise Investors in Q3 Earnings?
08:56AM  Can Agilent Technologies (A) Pull a Surprise in Q4 Earnings? Zacks
Nov-10-16 04:30PM  vTv Therapeutics to Participate in Upcoming Mizuho, Stifel and Piper Jaffray Conferences Business Wire
Nov-07-16 01:08PM  ETFs with exposure to vTv Therapeutics, Inc. : November 7, 2016
Nov-04-16 12:00PM  vTv Therapeutics, Inc. :VTVT-US: Earnings Analysis: Q3, 2016 By the Numbers : November 4, 2016
Nov-03-16 04:34PM  VTV THERAPEUTICS INC. Files SEC form 10-Q, Quarterly Report
05:08AM  VTv Therapeutics reports 3Q loss
Nov-02-16 04:47PM  VTV THERAPEUTICS INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exh -6.52%
04:30PM  vTv Therapeutics Reports Third Quarter Financial and Operational Results and Recent Highlights Business Wire
Oct-31-16 07:01AM  VTV THERAPEUTICS INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Creation of a Direct Financial
Oct-24-16 08:30AM  vTv Therapeutics to Present at Peptide Therapeutics Symposium Business Wire
Oct-03-16 07:30AM  vTv Therapeutics to Present at Neuro Advance Boston Business Wire
Sep-26-16 11:46AM  vTv Therapeutics Shares Initiated With Buy Rating, $13 Target
07:14AM  Coverage initiated on vTv Therapeutics by H.C. Wainwright
Sep-08-16 07:00AM  vTv Therapeutics to Present at the Rodman & Renshaw Global Investment Conference Business Wire
Sep-07-16 07:00AM  vTv Therapeutics Completes Enrollment of Part A of Pivotal Phase 3 Trial Evaluating Azeliragon for the Treatment of Patients with Mild Alzheimers Disease Business Wire
Sep-02-16 07:00AM  vTv Therapeutics to Present at the International Psychogeriatric Association International Congress Business Wire
Aug-17-16 06:05AM  VTV THERAPEUTICS INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exh
Aug-16-16 07:00AM  vTv Therapeutics Completes Enrollment of Phase 2 Trial Evaluating TTP273 for the Treatment of Type 2 Diabetes Business Wire
Aug-12-16 05:45PM  [$$] Clinical Development News, Aug. 8-12 at The Wall Street Journal
Aug-11-16 06:08AM  VTV THERAPEUTICS INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits
Aug-10-16 07:50AM  CORRECTING and REPLACING vTv Therapeutics Announces Positive Topline Results from Phase 2b Study of Glucokinase Activator TTP399 in Type 2 Diabetes Business Wire +6.36%
Aug-09-16 12:26PM  vTv Therapeutics, Inc. :VTVT-US: Earnings Analysis: Q2, 2016 By the Numbers : August 9, 2016
Aug-03-16 06:25AM  VTv Therapeutics reports 2Q loss
Aug-02-16 04:19PM  VTV THERAPEUTICS INC. Files SEC form 10-Q, Quarterly Report
Jul-27-16 05:15PM  vTv Therapeutics Announces Presentation of Phase 2b Azeliragon Results at the 2016 Alzheimers Association International Conference (AAIC) Business Wire
Jul-22-16 03:28PM  ETFs with exposure to vTv Therapeutics, Inc. : July 22, 2016
Jul-14-16 09:00AM  vTv Therapeutics Announces Phase 2b Azeliragon Data Selected for Oral Presentation at the 2016 Alzheimers Association International Conference Business Wire -7.01%
Jul-06-16 07:00AM  vTv Therapeutics to Present at Cantor Fitzgerald's 2nd Annual Healthcare Conference Business Wire
Jun-14-16 07:00AM  vTv Therapeutics Presents Positive Results from a Pilot Study of its Glucokinase Activator at American Diabetes Association 76th Scientific Sessions Business Wire
Jun-07-16 11:10AM  vTv Therapeutics, Inc. :VTVT-US: Earnings Analysis: Q1, 2016 By the Numbers : June 7, 2016
May-16-16 04:02PM  VTV THERAPEUTICS INC. Files SEC form 8-K, Submission of Matters to a Vote of Security Holders
May-13-16 08:37AM  VTV THERAPEUTICS INC. Files SEC form 10-Q, Quarterly Report
May-12-16 04:52PM  VTv Therapeutics reports 1Q loss -5.48%
04:34PM  VTV THERAPEUTICS INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exh
04:05PM  vTv Therapeutics Reports First Quarter Financial and Operational Results Business Wire
May-05-16 06:20AM  VTV THERAPEUTICS INC. Files SEC form 8-K, Unregistered Sale of Equity Securities
Apr-20-16 07:00AM  vTv Therapeutics Presents Data on Two Diabetes Candidates at Keystone Symposia on New Therapeutics for Diabetes and Obesity Business Wire
Apr-12-16 07:00AM  vTv Therapeutics Announces Presentations on its Diabetes Product Candidates TTP273 and TTP399 at the Keystone Symposia on New Therapeutics for Diabetes and Obesity Business Wire
Apr-06-16 09:50AM  vTv Therapeutics, Inc. :VTVT-US: Earnings Analysis: 2015 By the Numbers
07:00AM  vTv Therapeutics to Present at the 15th Annual Needham Healthcare Conference Business Wire
Mar-21-16 04:01PM  VTV THERAPEUTICS INC. Files SEC form 8-K, Change in Directors or Principal Officers
Mar-04-16 11:38AM  VTV THERAPEUTICS INC. Files SEC form 10-K, Annual Report
10:35AM  vTv Therapeutics to Present at Two Investor Conferences in March Business Wire
Mar-01-16 06:09PM  VTV THERAPEUTICS INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exh
07:15AM  VTv Therapeutics reports 4Q loss
07:00AM  vTv Therapeutics Reports Fourth Quarter and Full Year 2015 Financial and Operational Results and Recent Highlights Business Wire
Feb-23-16 04:02PM  VTV THERAPEUTICS INC. Files SEC form 8-K, Unregistered Sale of Equity Securities -6.45%
Feb-22-16 07:00AM  vTv Therapeutics Reports Preclinical and Clinical Results on its Diabetes Candidate TTP273 Business Wire
Feb-09-16 04:05PM  vTv Therapeutics Completes Enrollment of Phase 2b Trial Evaluating TTP399 for the Treatment of Type 2 Diabetes Business Wire
12:06PM  How Did Microsofts Stock Respond to 2Q16 Results?
11:01AM  Is a Surprise Coming for vTv Therapeutics (VTVT) This Earnings Season?
Feb-02-16 03:14PM  Microsofts Fiscal 2Q16 Earnings Beat Expectations -5.10%
10:06AM  Why Did ServiceNows Stock Fall by 20% after the Results?
Jan-28-16 04:25PM  vTv Therapeutics to Present at the 18th Annual BIO CEO & Investor Conference at noodls
Biotech developing treatments for Alzheimer's disease and type 2 diabetes.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
SAVAS PAUL GDirectorDec 07Buy4.575,00022,85786,781Dec 07 07:47 PM
SAVAS PAUL GDirectorDec 06Buy4.5510,00045,50081,781Dec 07 07:47 PM
PERELMAN RONALD O10% OwnerAug 22Buy4.5720,00091,3242,565,666Aug 24 05:49 PM
PERELMAN RONALD O10% OwnerAug 16Buy4.9710,00049,6782,545,666Aug 16 06:16 PM
PERELMAN RONALD O10% OwnerAug 15Buy4.8815,00073,2292,535,666Aug 15 06:18 PM
PERELMAN RONALD O10% OwnerAug 14Buy4.6535,000162,7362,520,666Aug 15 06:18 PM
PERELMAN RONALD O10% OwnerAug 11Buy4.4825,000111,9032,485,666Aug 14 04:27 PM
PERELMAN RONALD O10% OwnerAug 10Buy3.9860,000238,9622,460,666Aug 14 04:27 PM
SAVAS PAUL GDirectorMay 15Buy5.171,9009,82771,781May 15 07:30 PM
SAVAS PAUL GDirectorMay 12Buy5.201,1005,71669,881May 15 07:30 PM
SAVAS PAUL GDirectorMar 31Buy6.542,34615,33368,781Apr 03 06:54 PM
SAVAS PAUL GDirectorMar 30Buy6.487,65449,63266,435Apr 03 06:54 PM